ClinicalTrials.gg
CompletedNCT01955980Updated Apr 12, 2022Results posted

Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis

A Phase 1/2 interventional study of Budesonide and Budesonide in Rhinosinusitis, sponsored by Pari Pharma GmbH. Completed at 3 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-04-12.

Sponsored by Pari Pharma GmbH · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 21 studies in Rhinosinusitis with a site in Germany — 3 open to participants now, 7 under way, 4 of them phase 3. Rhinosinusitis · Germany.

Enrollment
13th of 15
19 · median 216
Started
2015
the only one that year
Phase 1/2
2 of 21
none open now
Registered
7th of 21
by date
Lead sponsor
2 of 21
Pari Pharma GmbH

Among the 21 studies in Rhinosinusitis with a site in Germany, this one is the 13th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2015, is one of 2 in phase 1/2, and was the 7th registered.

Rhinosinusitis

252 studies on the registry are indexed under Rhinosinusitis; 70 are open to participants now.

Browse Rhinosinusitis studies →

Open to participants now

3 of the 21 studies in Rhinosinusitis with a site in Germany are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 34 Rhinosinusitis studies recruiting now, 15 (44%) set no upper age limit and 13 (38%) stop at 75 or younger; 4 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Rhinosinusitis with a site in Germany, or all of them as a file.
02

Study summary

The study should create data for the selection of a clinically relevant endpoint to assess the potential of Buparid/PARI SINUS to postpone sinus surgery in patients with chronic Rhinosinusitis.

Read the detailed description

The objective of this study is to analyse whether Buparid/PARI SINUS has a higher potential to avoid or postpone sinus surgery in adult patients with CRS than Standard of Care therapy with Budes® Nasal Spray. The results of this study are expected to provide estimates for a proper sample size calculation to conduct a pivotal study.

03

Conditions studied

  • Rhinosinusitis

Browse trials for

Keywords

  • CRS
  • without polyposis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with confirmed diagnosis of chronic rhinosinusitis
  • Patient without alternative other than sinus surgery
  • Patient's written obtained prior to any screening or study-specific procedure
  • Male or female, ≥ 18 years of age
  • Patient is able to undergo nasal therapy without restrictions
  • Capable to correctly use the PARI SINUS device
  • Capable of understanding the purpose and risk of the clinical trial
  • Female patients with must have a negative urine pregnancy test prior to first IMP administration.
  • Patient is able to participate in the study according to Investigator's opinion

Exclusion criteria

Exclusion Criteria:

  • Patients with cystic fibrosis
  • Patients with polyposis nasi grade I-IV
  • Patients with prior FESS (Functional Endoscopic Sinus Surgery)
  • Pregnant or breastfeeding women
  • Any active invasive bacterial, viral or fungal infection within one week prior to first medicinal product (IMP) administration
  • No abnormal parameters of vital signs, blood biochemistry or renal/hepatic function
  • Unlikely to comply with visits, inhalation procedures or other measurements scheduled in the protocol
  • Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to first administration of IMP
  • Any co-existing medical condition that in the Investigator's judgement will substantially increase the risk associated with the patient's participation in the clinical trial
  • Psychiatric disorders or altered mental status precluding understanding of the process and/or completion of the necessary procedures
  • Drug or alcohol abuse
  • End-stage
  • Known to Budesonide
  • Patients with oral therapy within the last 3 months
  • Patients needing > 1 mg/day Budesonide (or steroidal equivalent) for therapy of asthma
  • Patients on therapy with leukotriene-receptor antagonists, decongestants, antihistamines or antibiotics
  • Patients with frequent epistaxis (> 1 episode per week)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Buparid; Treatment A

    Buparid 1mg budesonide/2 ml nebulizer solution

    Drug: Budesonide

  • Active comparator
    Budes; Treatment B

    Budes Nasal Spray 50 µg budesonide/pump

    Drug: Budesonide

Interventions

06

What researchers measure

Primary outcomes

  1. Change of Inflammation of the Nasal Mucosa and Paranasal Sinus

    Inflammation of the nasal mucosa and paranasal sinus was assessed using the Lund-Mackay score based on magnetic resonance imaging. The score can take on values between 0 and 24 points, with higher values indicating more severe thickness of the mucosa or opacification. The outcome investigated is the intraindividual mean score of 2 independent raters assessing the same images.

    Time frame: Change from Baseline to week 8

Secondary outcomes

  1. Health-specific Quality of Life

    Health-specific quality of life was assessed by means of the self-rated, 20-item Sino-Nasal Outcome Test (SNOT-20). The SNOT-20 total score has a (theoretical) range of 0 - 100 points, with higher scores indicating more severe impairment. Presented are the mean values of the SNOT-20 total score after 48 weeks minus value at day 0 (baseline).

    Time frame: change of SNOT-20 total score from baseline to week 48

  2. Nasal Obstruction

    Nasal obstruction was assessed using the method of rhinomanometry by measuring the positive nasal inspiratory flow (PNIF). For the assessment the subject had to inhale maximally through the nose three times and the highest value of flow rate was recorded after 4 weeks and 8 weeks of treatment.

    Time frame: 4 weeks / 8 weeks

  3. Inflammation of the Nasal Mucosa and Paranasal Sinus

    Determination of the thickness of the mucosa using Magnetic Resonance Imaging

    Time frame: Changes from Baseline at Week 8

  4. Safety Assessment

    Treatment-emergent adverse events

    Time frame: 48 weeks

07

Results

Posted Apr 12, 2022

Participant flow

Participant flow — Overall Study
MilestoneBuparid; Treatment ABudes; Treatment B
Started109
Completed109
Not completed00

Outcome measures

PrimaryChange of Inflammation of the Nasal Mucosa and Paranasal Sinus

Inflammation of the nasal mucosa and paranasal sinus was assessed using the Lund-Mackay score based on magnetic resonance imaging. The score can take on values between 0 and 24 points, with higher values indicating more severe thickness of the mucosa or opacification. The outcome investigated is the intraindividual mean score of 2 independent raters assessing the same images.

Time frame:
Change from Baseline to week 8
Reported as:
Median · score on a scale
Change of Inflammation of the Nasal Mucosa and Paranasal Sinus
score on a scaleBuparid; Treatment ABudes; Treatment B
Change of Inflammation of the Nasal Mucosa and Paranasal Sinus0 (-2 to 5.5)-0.8 (-5.5 to 4.5)
SecondaryHealth-specific Quality of Life

Health-specific quality of life was assessed by means of the self-rated, 20-item Sino-Nasal Outcome Test (SNOT-20). The SNOT-20 total score has a (theoretical) range of 0 - 100 points, with higher scores indicating more severe impairment. Presented are the mean values of the SNOT-20 total score after 48 weeks minus value at day 0 (baseline).

Time frame:
change of SNOT-20 total score from baseline to week 48
Reported as:
Mean · score on a scale
Health-specific Quality of Life
score on a scaleBuparid; Treatment ABudes; Treatment B
Health-specific Quality of Life17.1 (5.5 to 28.7)22.9 (10.5 to 35.3)
SecondaryNasal Obstruction

Nasal obstruction was assessed using the method of rhinomanometry by measuring the positive nasal inspiratory flow (PNIF). For the assessment the subject had to inhale maximally through the nose three times and the highest value of flow rate was recorded after 4 weeks and 8 weeks of treatment.

Time frame:
4 weeks / 8 weeks
Reported as:
Mean · ml/sec
Nasal Obstruction
ml/secBuparid; Treatment ABudes; Treatment B
Mean flow rate after 4 weeks542.4 (521 to 664)582.0 (447 to 717)
Mean flow rate after 8 weeks461.5 (320 to 602)551.5 (408 to 694)
SecondaryInflammation of the Nasal Mucosa and Paranasal Sinus

Determination of the thickness of the mucosa using Magnetic Resonance Imaging

Time frame:
Changes from Baseline at Week 8

Results for this outcome have not been posted.

SecondarySafety Assessment

Treatment-emergent adverse events

Time frame:
48 weeks
Reported as:
Count of participants · Participants
Safety Assessment
ParticipantsBuparid; Treatment ABudes; Treatment B
Safety Assessment66

Adverse events

Collected over Each participant has been monitored for adverse events up to 48 weeks. All patients withdrawn from the study will be followed-up for AEs or SAEs for further 2 weeks or 4 weeks, respectively.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Buparid; Treatment A0/10 (0%)1/10 (10%)5/10 (50%)
Budes; Treatment B0/9 (0%)0/9 (0%)6/9 (66.7%)
Most frequent serious events
Most frequent serious events
EventBuparid; Treatment ABudes; Treatment B
AneurysmVascular disorders1/100/9
Most frequent other events
Most frequent other events
EventBuparid; Treatment ABudes; Treatment B
EpistaxisRespiratory, thoracic and mediastinal disorders0/102/9
Nasal DrynessRespiratory, thoracic and mediastinal disorders0/101/9
HeadacheNervous system disorders0/101/9
RhinitisInfections and infestations1/101/9
SinusitisInfections and infestations1/101/9
InfluenzaInfections and infestations1/101/9
CoughRespiratory, thoracic and mediastinal disorders1/100/9
DepressionPsychiatric disorders1/100/9
TonsillitisInfections and infestations1/100/9

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Buparid; Treatment ABudes; Treatment BTotal
<=18 years000
Between 18 and 65 years10919
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Buparid; Treatment ABudes; Treatment BTotal
Female5510
Male549
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Buparid; Treatment ABudes; Treatment BTotal
Count of participants——0
Region of Enrollment
Region of Enrollment(Participants)Buparid; Treatment ABudes; Treatment BTotal
Germany10919
08

Study locations

3 sites
  • University Göttingen
    Göttingen, 37099, Germany
  • UNIVERSITÄTSMEDIZIN der Johannes Gutenberg-Universität Mainz
    Mainz, 55131, Germany
  • University Munich
    Munich, 81377, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2015 to primary completion in Sep 2018, 35 months.

Results were first posted in Apr 2022, 3 years 6 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 30, 2013
First posted
Oct 8, 2013
StartActual
Oct 27, 2015
Primary completionActual
Sep 27, 2018
CompletionActual
Jul 29, 2021
Results first posted
Apr 12, 2022
Last update
Apr 12, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 12, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01955980
Lead sponsor
Pari Pharma GmbH
Responsible party
Sponsor
First posted
Oct 8, 2013
Start date
Oct 27, 2015
Primary completion
Sep 27, 2018
Completion
Jul 29, 2021
Results posted
Apr 12, 2022
Last update
Apr 12, 2022

Study contacts

Martin Canis, MD
principal investigator · University Goettingen

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Budesonide

Start the discussion